Case History: Chantix™/Champix™ (Varenicline Tartrate), a Nicotinic Acetylcholine Receptor Partial Agonist as a Smoking Cessation Aid

被引：21
|
作者：
Coe, Jotham W. [1 ]
Rollema, Hans [1 ]
O'Neill, Brian T. [1 ]
机构：
[1] Pfizer Global Res & Dev, Groton Labs, Groton, CT 06340 USA
来源：
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 44 | 2009年 / 44卷
关键词：
RANDOMIZED CONTROLLED-TRIAL; 10-SUBSTITUTED CYTISINE DERIVATIVES; SUSTAINED-RELEASE BUPROPION; DISCRIMINATIVE STIMULUS; DOSE PHARMACOKINETICS; CHOLINERGIC-RECEPTOR; HEALTHY SMOKERS; BETA-2; SUBUNIT; IN-VIVO; (-)-CYTISINE;
D O I：
10.1016/S0065-7743(09)04404-2
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
[No abstract available]
引用
收藏
页码：71 / +
页数：32
相关论文
共 50 条
  • [31] Pharmacogenetic study of the nicotinic acetylcholine receptor subunit genes and smoking cessation among smokers receiving Varenicline treatment
    Lin, M.
    Wu, C.
    Wu, T.
    Wu, Y. W.
    Chang, Y.
    Lai, C.
    Hsuch, K.
    Leu, H.
    Chen, L.
    Tsai, Y. I.
    Liang, K.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 553 - 553
  • [32] Smoking Cessation in COPD Patients by a Selective Partial Nicotinic Agonist
    Ianosi, Edith Simona
    Postolache, Paraschiva
    Macovei, Luana Andreea
    Szathmary, Mioara
    Szasz, Simona
    Nemes, Roxana Maria
    Jimborean, Gabriela
    REVISTA DE CHIMIE, 2018, 69 (07): : 1766 - 1769
  • [33] DECAMETHONIUM IS A PARTIAL AGONIST AT THE NICOTINIC ACETYLCHOLINE-RECEPTOR
    LIU, Y
    DILGER, JP
    SYNAPSE, 1993, 13 (01) : 57 - 62
  • [34] Effects of the Nicotinic Partial Agonist Varenicline on Smoking Lapse in Smokers with and without Schizophrenia
    Coles, Alexandria
    Kozak, Karolina
    Sharif-Razi, Maryam
    Mckee, Sherry
    George, Tony
    BIOLOGICAL PSYCHIATRY, 2017, 81 (10) : S73 - S73
  • [35] New progress in nicotinic acetylcholine receptor modulation for smoking cessation
    不详
    DRUG NEWS & PERSPECTIVES, 2006, 19 (05) : 297 - 298
  • [36] Nicotinic acetylcholine receptor variation and response to smoking cessation therapies
    Bergen, Andrew W.
    Javitz, Harold S.
    Krasnow, Ruth
    Nishita, Denise
    Michel, Martha
    Conti, David V.
    Liu, Jinghua
    Lee, Won
    Edlund, Christopher K.
    Hall, Sharon
    Kwok, Pui-Yan
    Benowitz, Neal L.
    Baker, Timothy B.
    Tyndale, Rachel F.
    Lerman, Caryn
    Swan, Gary E.
    PHARMACOGENETICS AND GENOMICS, 2013, 23 (02): : 94 - 103
  • [37] Dianicline, a Novel α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, for Smoking Cessation: A Randomized Placebo-Controlled Clinical Trial
    Tonstad, Serena
    Holme, Ingar
    Tonnesen, Philip
    NICOTINE & TOBACCO RESEARCH, 2011, 13 (01) : 8 - 13
  • [38] Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation:: A randomized controlled trial (vol 296, pg 56, 2006)
    Jorenby, D. E.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (11): : 1355 - 1355
  • [39] Varenicline Is a Potent Partial Agonist at α6β2* Nicotinic Acetylcholine Receptors in Rat and Monkey Striatum
    Bordia, Tanuja
    Hrachova, Maya
    Chin, Matthew
    McIntosh, J. Michael
    Quik, Maryka
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2012, 342 (02): : 327 - 334
  • [40] Discovery and pharmacology of varenicline: An a4b2 nAChR partial agonist for smoking cessation
    Rollema, H.
    Coe, J. W.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S55 - S55
12345